1. Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists
- Author
-
Eugene T. Grygielko, Shawn P. Williams, Lindsay E. Glace, Jeffrey D. Bray, Chaya Duraiswami, James S. Frazee, Kevin P. Madauss, David G. Washburn, Tram H. Hoang, Leahann Lapinski, Walter Trizna, Nicholas J. Laping, and Scott K. Thompson
- Subjects
Agonist ,Pyrrolidines ,medicine.drug_class ,Stereochemistry ,Clinical Biochemistry ,Pharmaceutical Science ,Administration, Oral ,Crystallography, X-Ray ,Biochemistry ,Partial agonist ,Pyrrolidine ,chemistry.chemical_compound ,Drug Discovery ,Progesterone receptor ,medicine ,Animals ,Computer Simulation ,Molecular Biology ,Hormone binding protein ,Binding Sites ,Organic Chemistry ,Rational design ,Protein Structure, Tertiary ,Rats ,chemistry ,Nuclear receptor ,Estrogen ,Drug Design ,Models, Animal ,Molecular Medicine ,Receptors, Progesterone - Abstract
Using the X-ray crystal structure of an amide-based progesterone receptor (PR) partial agonist bound to the PR ligand binding domain, a novel PR partial agonist class containing a pyrrolidine ring was designed. Members of this class of N-alkylpyrrolidines demonstrate potent and highly selective partial agonism of the progesterone receptor, and one of these analogs was shown to be efficacious upon oral dosing in the OVX rat model of estrogen opposition.
- Published
- 2009